Christopher Evans & Alan Goodman
11 April 2003

                        Oxford Glycosciences PLC ('OGS')

Sir Christopher Evans and Alan Goodman confirm that they have now completed
their detailed due diligence on OGS. Based on the results of such final detailed
due diligence, Sir Christopher and Mr Goodman have concluded that an offer at a
value in excess of that currently offered by the outstanding offer from Celltech
Group PLC ('Celltech') is not a viable proposition. They are, therefore, today
formally withdrawing their interest in OGS. However, they intend to maintain a
watching brief on the situation and reserve the right to make an offer for OGS
should Celltech's offer lapse.

Sir Christopher and Mr Goodman remain convinced of the benefits of consolidation
in the UK biotech sector, particularly by way of public to private transactions,
and they are currently actively pursuing a number of other attractive
opportunities in the sector.

11 April 2003